We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Redx Pharma

Kadmon acquisition has read across for RXC007

Lighthouse | 08 September 2021

Redx Pharma

All that Jazz: $3m milestone boosts cash and confidence

Update | 07 September 2021


Accelerated protocols could be a game changer

Outlook | 19 August 2021


Lead therapeutic asset AVA6000 enters the clinic

Lighthouse | 11 August 2021


Strategic collaboration for Tazverik in Greater China

Lighthouse | 10 August 2021

Allergy Therapeutics

Biomarker data confirm VLP Peanut hypoallergenicity

Lighthouse | 03 August 2021


CTA approval confirms H221 COVIDITY Phase I start

Lighthouse | 30 July 2021


First custom CTC assay development contract

Lighthouse | 29 July 2021

Redx Pharma

RXC004 2mg dose selected for Phase II trials

Lighthouse | 27 July 2021

Redx Pharma

Rezurock approval has positive read across for Redx

Lighthouse | 19 July 2021
397 results found.